viewCytoDyn Inc.

CytoDyn greenlit from Health Canada to file BLA for leronlimab as combination HIV therapy

CytoDyn Inc. (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotech has been approved by Health Canada to file its Biologics License Application (BLA) for leronlimab as a combination HIV therapy for multi-drug resistance HIV patients in Canada.

What's more, Pourhassan says the group will change its flagship drug leronlimab's name to VYROLOGIX, and nine of the company’s trademark applications to register the mark have now successfully passed through formal examination. Final approval of Vyrologix as the name for leronlimab is conditional on FDA approval of the BLA and new drug application.

Quick facts: CytoDyn Inc.

Price: 4.54 USD

Market: OTCQB
Market Cap: $2.72 billion

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events


The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of CytoDyn Inc. named herein, including the promotion by the Company of CytoDyn Inc. in any Content on the Site, the Company receives from said...


CytoDyn achieves 75% enrollment for its severe-to-critical coronavirus...

CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive the biotechnology company has achieved the enrollment of 293 patients with severe-to-critical coronavirus symptoms, meeting the criteria for a second interim analysis by the Data Safety Monitoring Committee (DSMC). Pourhassan says...

on 11/23/2020

2 min read